Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2026 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | -461.17K | - |
| Net profit | -1.81M | - |
| EBITDA | -1.34M | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €14.94M |
Number of shares | 389.72M |
52-week high/low | €0.12 - €0.034 |
| Dividends | No |
Beta | 1.12 |
P/E ratio | -4.46 |
PEG ratio | 0.32 |
P/B ratio | 1.42 |
P/S ratio | 0.00 |
Company profile
NeuroScientific Biopharmaceuticals Limited entwickelt diagnostische und therapeutische Behandlungen für neurodegenerative Krankheiten durch präklinische Studien mit patentierten Technologien. Zu den führenden Arzneimittelkandidaten des Unternehmens gehört EmtinB zur Behandlung von neurodegenerativer Demenz und Alzheimer-Krankheit sowie von degenerativen Erkrankungen des Sehnervs. NeuroScientific Biopharmaceuticals Limited wurde im Jahr 2002 gegründet und hat seinen Sitz in Cottesloe, Australien.
| Name | NEUROSCIENTIFIC BIOPH. |
| CEO | Nathan Smith |
| Headquarters | Perth,
wa Australia |
| Website | |
| IPO | 05/23/2016 |
| Employees | 9 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Australian Securities Exchange Ltd | NSB.AX |
Discover assets
Shareholders of NEUROSCIENTIFIC BIOPH. also invest in the following assets
